15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

  title={15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.},
  author={Christian Winther Eskelund and Arne Kolstad and Mats Jerkeman and Riikka R{\"a}ty and A. B. Laurell and Sandra Eloranta and Karin E Smedby and Simon Husby and Lone Bredo Pedersen and Niels Smedegaard Andersen and Mikael Eriksson and Eva K Kimby and Hans Herluf N\orregaard Bentzen and Outi Kuittinen and Grete Fossum Lauritzsen and Herman Nilsson-Ehle and Elisabeth Methner Ralfkiaer and Mats Ehinger and Christer Sundstr{\"o}m and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Christopher T. Workman and Christian Garde and Erkki Elonen and Peter deNully Brown and Kirsten Gr\onbaek and Christian Hartmann Geisler},
  journal={British journal of haematology},
  volume={175 3},
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 11·4 years: For all patients on an intent-to-treat basis, the median… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Journal of experimental & clinical cancer research : CR • 2018
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 30 references

The role of targeted treatment in mantle cell lymphoma : is transplant dead or alive ?

M. H. Dreyling, G. Lenz, +14 authors H. Wolfgang
Haematologica • 2016

High-dose cytarabine in mantle cell lymphoma.

Clinical advances in hematology & oncology : H&O • 2015

Ritux - imab plus hyper - CVAD alternating with MTX / AraC in patients with newly diagnosed mantle cell lymphoma : 15 - year follow - up of a phase II study from the MD Anderson Cancer Center

R. Delarue, C. Haioun, +7 authors F. Lefrere
British Journal of Haematology • 2015

Similar Papers

Loading similar papers…